Grandeur Peak Global Advisors LLC Takes $15.45 Million Position in LeMaitre Vascular, Inc. $LMAT

Grandeur Peak Global Advisors LLC bought a new stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) in the 2nd quarter, HoldingsChannel reports. The firm bought 161,010 shares of the medical instruments supplier’s stock, valued at approximately $15,451,000. LeMaitre Vascular accounts for about 3.1% of Grandeur Peak Global Advisors LLC’s investment portfolio, making the stock its 9th largest position.

A number of other hedge funds and other institutional investors have also recently modified their holdings of LMAT. BlackRock Inc. purchased a new stake in LeMaitre Vascular during the second quarter valued at about $314,075,000. Vanguard Group Inc. boosted its stake in shares of LeMaitre Vascular by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 1,622,033 shares of the medical instruments supplier’s stock valued at $131,547,000 after purchasing an additional 21,946 shares during the period. Conestoga Capital Advisors LLC grew its holdings in shares of LeMaitre Vascular by 3.6% in the first quarter. Conestoga Capital Advisors LLC now owns 1,476,813 shares of the medical instruments supplier’s stock worth $161,224,000 after purchasing an additional 51,825 shares during the last quarter. First Trust Advisors LP boosted its holdings in shares of LeMaitre Vascular by 6.2% during the first quarter. First Trust Advisors LP now owns 998,071 shares of the medical instruments supplier’s stock worth $108,959,000 after purchasing an additional 57,931 shares during the period. Finally, State Street Corp grew its stake in shares of LeMaitre Vascular by 0.8% in the fourth quarter. State Street Corp now owns 806,993 shares of the medical instruments supplier’s stock worth $65,447,000 after purchasing an additional 6,130 shares during the last quarter. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

LeMaitre Vascular Stock Up 0.1%

LMAT stock opened at $79.67 on Friday. The company has a debt-to-equity ratio of 0.40, a current ratio of 16.31 and a quick ratio of 13.96. LeMaitre Vascular, Inc. has a 1-year low of $78.27 and a 1-year high of $118.01. The stock has a market capitalization of $1.82 billion, a P/E ratio of 27.95, a P/E/G ratio of 2.30 and a beta of 0.53. The business has a fifty day moving average price of $93.31 and a 200-day moving average price of $99.46.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Tuesday, August 4th. The medical instruments supplier reported $0.74 earnings per share for the quarter, missing analysts’ consensus estimates of $0.81 by ($0.07). LeMaitre Vascular had a return on equity of 15.63% and a net margin of 25.02%.The business had revenue of $70.38 million during the quarter, compared to analysts’ expectations of $71.47 million. During the same period last year, the firm posted $0.60 EPS. LeMaitre Vascular’s quarterly revenue was up 9.6% compared to the same quarter last year. Equities analysts forecast that LeMaitre Vascular, Inc. will post 2.89 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 3rd. Stockholders of record on Thursday, August 20th will be paid a $0.25 dividend. This represents a $1.00 dividend on an annualized basis and a dividend yield of 1.3%. The ex-dividend date is Thursday, August 20th. LeMaitre Vascular’s dividend payout ratio (DPR) is 35.09%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Citigroup reissued a “market outperform” rating on shares of LeMaitre Vascular in a research note on Tuesday, July 21st. Weiss Ratings cut LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, August 14th. Zacks Research downgraded LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Wall Street Zen downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Finally, Citizens Jmp lifted their price objective on LeMaitre Vascular from $118.00 to $127.00 and gave the company a “market outperform” rating in a research note on Wednesday, May 6th. Three research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $110.60.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.